This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
TARO Aperçu des actions
A science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 3/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Taro Pharmaceutical Industries Ltd. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$42.97 |
| Plus haut sur 52 semaines | US$45.76 |
| Plus bas sur 52 semaines | US$32.67 |
| Bêta | 0.56 |
| 1Variation sur 1 mois | 0.66% |
| Variation sur 3 mois | 1.97% |
| Variation sur 1 an | 10.21% |
| 3Variation sur 3 ans | -40.56% |
| Variation sur 5 ans | -50.36% |
| Évolution depuis l'introduction en bourse | 759.40% |
Nouvelles et mises à jour récentes
Recent updates
Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity
Dec 12Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)
Aug 16Taro Pharmaceutical: Potential Value In Sun Pharma Offer
Jun 02Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold
Feb 24Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M
Jan 24Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M
Oct 28Taro Pharmaceutical hits 52-week low; down 28% YTD
Aug 15Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M
Jul 27Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card
Jul 14We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative
Aug 03
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns
Jan 26
Rendement pour les actionnaires
| TARO | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 0.4% | -2.7% | 0.9% |
| 1Y | 10.2% | 21.5% | 32.4% |
Rendement vs Industrie: TARO underperformed the US Pharmaceuticals industry which returned 18.8% over the past year.
Rendement vs marché: TARO underperformed the US Market which returned 24.1% over the past year.
Volatilité des prix
| TARO volatility | |
|---|---|
| TARO Average Weekly Movement | 0.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: TARO has not had significant price volatility in the past 3 months.
Volatilité au fil du temps: TARO's weekly volatility (1%) has been stable over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1959 | 1,554 | Uday Baldota | www.taro.com |
Taro Pharmaceutical Industries Ltd. Résumé des fondamentaux
| TARO statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.62b |
| Bénéfices(TTM) | US$53.87m |
| Recettes(TTM) | US$629.18m |
30.0x
Ratio P/E2.6x
Ratio P/SLe site TARO est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| TARO compte de résultat (TTM) | |
|---|---|
| Recettes | US$629.18m |
| Coût des recettes | US$324.20m |
| Marge brute | US$304.98m |
| Autres dépenses | US$251.11m |
| Les revenus | US$53.87m |
Derniers bénéfices déclarés
Mar 31, 2024
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 1.43 |
| Marge brute | 48.47% |
| Marge bénéficiaire nette | 8.56% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de TARO?
Voir les performances historiques et les comparaisons